John Lindsey

Professor

The University of Texas Health Science Center at Houston

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

John Lindsey is a Professor at The University of Texas Health Science Center at Houston, USA. His research primarily focuses on multiple sclerosis, including the safety and efficacy of treatments, the immune response to Epstein-Barr virus, and the role of gut microbiota in autoimmune diseases. Lindsey's recent publications investigate diverse aspects of multiple sclerosis treatment and patient outcomes, contributing valuable insights to the field.

Articles (9)

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (4)

Emmanuelle Waubant

University of California

UNITED STATES

View details

Rajesh Gupta

Assistant Professor

UNITED STATES

View details

Assaf Gottlieb

The University of Texas Health Science Center at Houston

UNITED STATES

View details

Jerry Wolinsky

Emeritus Professor in Neurology

The University of Texas Health Science Center at Houston

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

John Lindsey

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

Safety, tolerability, and efficacy of diroximel fumarate in a cohort of Black patients with multiple sclerosis from the phase 3 EVOLVE-MS-1 study

Expanded T lymphocytes in the cerebrospinal fluid of multiple sclerosis patients are specific for Epstein-Barr-virus-infected B cells

The concentrations of antibodies to Epstein-Barr virus decrease during ocrelizumab treatment

Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study

Brain Antigens Stimulate Proliferation of T Lymphocytes With a Pathogenic Phenotype in Multiple Sclerosis Patients.

The cellular immune response against Epstein-Barr virus decreases during ocrelizumab treatment.

COVID-19 severity and outcome in multiple sclerosis: Results of a national, registry-based, matched cohort study.

Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial.

The Association of Gut Microbiota and Treg Dysfunction in Autoimmune Diseases.

Collaborators (4)

Emmanuelle Waubant

Rajesh Gupta

Assaf Gottlieb

Jerry Wolinsky

Make your next move.